Table 1.
Results of univariate statistical analysis
| Sample type | Characteristics | Engraftment ability (Y/N) | Engraftment intensity (hCD45+ %) | Engraftment latency (12/16 weeks) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n patients | Statistical test | Statistical significance | n patients | Statistical test | Statistical significance | n patients | Statistical test | Statistical significance | ||
| Diagnostic samples only | Mutations | |||||||||
| NPM1 | 19 of 46 | Fisher’s exact test | p = 0.4 | 11 of 22 | Mann Whitney | p = 0.1 | 11 of 22 | Fisher’s exact test | p = 0.4 | |
| FLT3-ITD | 11 of 47 | p = 0.7 | 6 of 22 | p = 0.7 | 6 of 22 | p = 1.0 | ||||
| DNMT3A | 9 of 46 | p = 0.3 | 6 of 22 | p = 0.8 | 6 of 22 | p = 1.0 | ||||
| NRAS | 9 of 40 | p = 0.5 | 4 of 22 | p = 0.5 | 4 of 22 | p = 1.0 | ||||
| CEBPA | 8 of 40 | p = 1.0 | 4 of 22 | p = 0.8 | 4 of 22 | p = 1.0 | ||||
| CEBPA biallelic | 4 of 40 | p = 1.0 | 2 of 22 | N/A | 2 of 22 | p = 1.0 | ||||
| FLT3-TKD | 7 of 40 | p = 0.2 | 2 of 22 | N/A | 2 of 22 | p = 1.0 | ||||
| TET2 | 6 of 40 | p = 0.7 | 4 of 22 | p = 0.3 | 4 of 22 | p = 1.0 | ||||
| ASXL1 | 5 of 40 | p = 0.7 | 3 of 22 | p = 0.6 | 3 of 22 | p = 1.0 | ||||
| IDH1 | 4 of 40 | p = 0.3 | 1 of 22 | N/A | 1 of 22 | p = 1.0 | ||||
| IDH2 | 4 of 40 | p = 0.6 | 3 of 22 | p = 0.09 | 3 of 22 | p = 1.0 | ||||
| U2AF1 | 3 of 40 | p = 0.6 | 2 of 22 | N/A | 2 of 22 | p = 0.09 | ||||
| SRSF2 | 2 of 40 | p = 1.0 | 1 of 22 | N/A | 1 of 22 | p = 1.0 | ||||
| TP53 | 1 of 40 | p = 1.0 | 1 of 22 | N/A | 1 of 22 | p = 1.0 | ||||
| RUNX1 | 1 of 40 | p = 1.0 | 0 of 22 | N/A | 0 of 22 | N/A | ||||
| DNMT3Amut/NPM1mut | 5 of 46 | p = 0.02 | 5 of 22 | p = 0.8 | 5 of 22 | p = 1.0 | ||||
| DNMT3Amut/FLT3-ITDmut | 3 of 46 | p = 0.6 | 2 of 22 | p = 0.4 | 2 of 22 | p = 1.0 | ||||
| NPM1mut/FLT3-ITDmut | 9 of 46 | p = 0.7 | 5 of 22 | p = 0.7 | 5 of 22 | p = 1.0 | ||||
| NPM1mut/FLT3-ITDneg | 10 of 46 | p = 0.5 | 6 of 22 | p = 0.02 | 6 of 22 | p = 0.1 | ||||
| DNMT3Amut/NPM1mut/FLT3-ITDmut | 2 of 46 | p = 0.2 | 2 of 22 | N/A | 2 of 22 | p = 1.0 | ||||
| Patient-related | ||||||||||
| Diagnostic vs relapse samples | 47 vs 14 | Fisher’s exact test | p = 1.0 | 22 vs 7 | Mann Whitney | p = 0.03 | 22 vs 7 | Fisher’s exact test | p = 0.4 | |
| Diagnostic vs refractory samples | 47 vs 7 | p = 0.2 | 22 vs 1 | N/A | 22 vs 1 | N/A | ||||
| Achievement of clinical remission | 37 of 45 | p = 0.7 | 18 of 21 | p = 0.7 | 18 of 21 | p = 0.03 | ||||
| Occurrence of relapse | 16 of 45 | p = 0.8 | 8 of 21 | p = 0.1 | 8 of 21 | p = 0.7 | ||||
| Intermediate vs poor cytogenetic risk | 37 vs 10 | p = 0.7 | 18 vs 4 | p = 0.006 | 18 vs 4 | p = 0.08 | ||||
| Leukemia-related | ||||||||||
| Non-CN AML | 9 of 43 | Fisher’s exact test | p = 0.5 | 5 of 19 | Mann Whitney test | p = 0.4 | 5 of 19 | Fisher’s exact test | p = 1.0 | |
| Complex karyotype | 6 of 47 | p = 1.0 | 3 of 22 | p = 0.01 | 3 of 22 | p = 0.2 | ||||
| WBC PB | 47 | Mann Whitney | p = 0.1 | 22 | Pearson’s r | p = 0.4 | 22 | Mann Whitney | p = 0.9 | |
| PB blast % | 47 | p = 0.9 | 22 | p = 0.2 | 22 | p = 0.07 | ||||
| BM blast % | 47 | p = 0.8 | 22 | p = 0.1 | 22 | p = 0.3 | ||||
| CD34 expression on LEU | 47 | p = 0.2 | 22 | p = 0.3 | 22 | p = 0.3 | ||||
| CD33 expression on LEU | 47 | p = 0.4 | 22 | p = 0.08 | 22 | p = 0.4 | ||||
| Sample-related | ||||||||||
| Total number of transplanted blasts | 46 | Mann Whitney | p = 0.1 | 22 | Pearson’s r | p = 0.4 | 22 | Mann Whitney | p = 0.7 | |
| Fresh vs cryopreserved | 11 vs 36 | Fisher’s exact test | p = 0.7 | 6 vs 16 | Mann Whitney | p = 0.2 | 6 vs 16 | Fisher’s exact test | p = 0.6 | |
| Diagnostic + refractory + relapse samples | Leukemia-related | |||||||||
| Non-CN AML | 15 of 57 | Fisher’s exact test | p = 0.4 | 8 of 24 | Mann Whitney test | p = 0.2 | 8 of 24 | Fisher’s exact test | p = 1.0 | |
| Complex karyotype | 10 of 67 | p = 0.3 | 6 of 30 | p = 0.01 | 6 of 30 | p = 0.7 | ||||
| WBC PB | 68 | Mann Whitney | p = 0.01 | 30 | Pearson’s r | p = 0.2 | 30 | Mann Whitney | p = 0.6 | |
| PB blast % | 68 | p = 0.09 | 30 | p = 0.2 | 30 | p = 0.06 | ||||
| BM blast % | 68 | p = 0.1 | 30 | p = 0.06 | 30 | p = 0.1 | ||||
| CD34 expression on LEU | 67 | p = 0.3 | 30 | p = 0.2 | 30 | p = 0.09 | ||||
| CD33 expression on LEU | 65 | p = 0.09 | 29 | p = 0.3 | 29 | p = 0.3 | ||||
| Sample-related | ||||||||||
| Total number of transplanted blasts | 67 | Mann Whitney | p = 0.02 | 30 | Pearson’s r | p = 0.5 | 30 | Mann Whitney | p = 0.9 | |
| Fresh vs cryopreserved | 13 vs 55 | Fisher’s exact test | p = 0.5 | 7 vs 23 | Mann Whitney | p = 0.2 | 7 vs 23 | Fisher’s exact test | p = 0.2 | |
The table shows association of AML characteristics with three engraftment outcomes—engraftment ability (categorical), engraftment intensity (continuous) and engraftment latency (categorical), for the group of 47 diagnostic samples (upper part) and the extended group of all 68 samples from patients at different disease stages (lower part). For the 68-sample group, only the effect of leukemia-related characteristics was examined
BM Bone marrow, CN AML AML with cytogenetic aberrations other than complex karyotype, LEU leukocytes, n count, N negative, N/A not analyzed, PB peripheral blood, WBC white blood count, Y positive